INTELLIGENT BIO SOLUTIONS INC.
For the period ended Jun 30, 2026. Filed Aug 19, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Aug 19, 2026
INBS$2.29+16.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONSOLIDATED BALANCE SHEETS
| As of June 30, | As of June 30, | |
|---|---|---|
| 2026 | 2025 | |
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $3,992,312 | $1,019,909 |
| Accounts receivable, net | 848,464 | 594,614 |
| Inventories, net | 418,577 | 635,215 |
| Research and development tax incentive receivable | 806,951 | 734,408 |
| Assets held for sale | - | 327,500 |
| Prepaid expenses and other current assets | 1,030,932 | 826,976 |
| Total current assets | 7,097,236 | 4,138,622 |
| Property and equipment, net | 294,399 | 251,325 |
| Operating lease right-of-use assets | 1,751,040 | 69,520 |
| Intangibles, net | 2,799,161 | 3,790,319 |
| Total assets | $11,941,836 | $8,249,786 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| Current liabilities | ||
| Accounts payable and accrued expenses | $4,130,213 | $4,534,246 |
| Current portion of operating lease liabilities | 147,005 | 84,659 |
| Current employee benefit liabilities | 651,706 | 534,990 |
| Notes payable | - | 197,146 |
| Total current liabilities | 4,928,924 | 5,351,041 |
| Employee benefit liabilities, less current portion | 49,931 | 84,921 |
| Operating lease liabilities, less current portion | 1,672,155 | - |
| Total liabilities | 6,651,010 | 5,435,962 |
| Commitments and contingencies (Note 15) | - | - |
| Shareholders’ equity | ||
| Common stock, $0.01 par value, 100,000,000 shares authorized, 2,905,615 and 2,905,603 shares issued and outstanding, as of June 30, 2026, respectively; 732,339 and 732,327 shares issued and outstanding, as of June 30, 2025, respectively* | 29,056 | 7,324 |
| Treasury stock, at cost, 12 shares as of June 30, 2026 and 2025, respectively* | (1) | (1) |
| Additional paid-in capital* | 80,992,006 | 65,849,822 |
| Accumulated deficit | (74,964,040) | (62,533,065) |
| Accumulated other comprehensive loss | (546,186) | (327,944) |
| Total consolidated Intelligent Bio Solutions Inc. equity | 5,510,835 | 2,996,136 |
| Non-controlling interest | (220,009) | (182,312) |
| Total shareholders’ equity | 5,290,826 | 2,813,824 |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $11,941,836 | $8,249,786 |
| * | Common stock and per share amounts have been retroactively adjusted to reflect a 1-for-10 reverse stock split effected on December 15, 2025, throughout the consolidated financial statements unless otherwise stated. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.